AbbVie Total Long Term Liabilities 2010-2024 | ABBV

AbbVie total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
  • AbbVie total long term liabilities for the quarter ending September 30, 2024 were $93.201B, a 3.29% increase year-over-year.
  • AbbVie total long term liabilities for 2023 were $86.473B, a 5.99% decline from 2022.
  • AbbVie total long term liabilities for 2022 were $91.98B, a 4.09% decline from 2021.
  • AbbVie total long term liabilities for 2021 were $95.899B, a 11.86% decline from 2020.
AbbVie Annual Total Long Term Liabilities
(Millions of US $)
2023 $86,473
2022 $91,980
2021 $95,899
2020 $108,807
2019 $81,702
2018 $50,559
2017 $49,048
2016 $51,682
2015 $38,211
2014 $14,378
2013 $17,827
2012 $16,869
2011 $1,692
2010 $1,670
2009 $
AbbVie Quarterly Total Long Term Liabilities
(Millions of US $)
2024-06-30 $93,201
2024-03-31 $99,305
2023-12-31 $86,473
2023-09-30 $89,319
2023-06-30 $90,230
2023-03-31 $93,651
2022-12-31 $91,980
2022-09-30 $92,586
2022-06-30 $94,025
2022-03-31 $94,376
2021-12-31 $95,899
2021-09-30 $106,748
2021-06-30 $106,694
2021-03-31 $104,817
2020-12-31 $108,807
2020-09-30 $110,151
2020-06-30 $110,152
2020-03-31 $82,143
2019-12-31 $81,702
2019-09-30 $50,174
2019-06-30 $48,767
2019-03-31 $50,691
2018-12-31 $50,559
2018-09-30 $53,698
2018-06-30 $47,792
2018-03-31 $48,731
2017-12-31 $49,048
2017-09-30 $49,120
2017-06-30 $48,726
2017-03-31 $51,822
2016-12-31 $51,682
2016-09-30 $51,054
2016-06-30 $52,299
2016-03-31 $38,415
2015-12-31 $38,211
2015-09-30 $41,156
2015-06-30 $37,093
2015-03-31 $14,272
2014-12-31 $14,378
2014-09-30 $17,174
2014-06-30 $17,510
2014-03-31 $17,744
2013-12-31 $17,827
2013-09-30 $17,800
2013-06-30 $17,547
2013-03-31 $17,446
2012-12-31 $16,869
2012-09-30 $1,693
2012-06-30 $1,365
2012-03-31 $1,396
2011-12-31 $1,692
2011-09-30
2011-06-30
2011-03-31
2010-12-31 $1,670
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $352.544B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51